There is a lack of actively targeting drug delivery carriers for the topical treatment of epidermal diseases, which results in drug waste and an increased incidence of toxic side effects in the clinic. We recently discovered that epidermal cells (HaCaT cells) have homologous targeting functions and developed HaCaT cell membrane-coated pH-sensitive micelles for therapeutic active targeting of skin disease. We encapsulated shikonin in these biomimetic nanocarriers and found that the nanocarriers accumulated mainly in the active epidermis when delivered with karaya gum-fabricated water-soluble microneedles. The nanocarriers were internalized by the target cells, resulting in swelling of histidine fragments with protonation and subsequent triggering of drug release, which increased the therapeutic efficacy of shikonin against imiquimod-induced psoriatic epidermal hyperplasia. This emerging biomimetic delivery strategy is a new approach for improving the treatment of skin diseases and is also very promising for use in the field of cosmetics. Additionally, we found abnormally high protein expression of Na⁺/K⁺-ATPase in diseased skin; thus, this protein may be a biomarker of psoriasis.

目前缺乏用于表皮疾病局部治疗的主动靶向给药载体，导致药物浪费和临床毒副作用发生率增加。我们最近发现表皮细胞（HaCaT 细胞）具有同源靶向功能，并开发了 HaCaT 细胞膜包被的 pH 敏感胶束，用于皮肤病的治疗性主动靶向。我们将紫草素封装在这些仿生纳米载体中，发现当用刺梧桐胶制造的水溶性微针递送时，纳米载体主要积聚在活性表皮中。纳米载体被靶细胞内化，导致组氨酸片段膨胀并质子化并随后触发药物释放，这增加了紫草素对咪喹莫特诱导的银屑病表皮增生的治疗效果。这种新兴的仿生传递策略是一种改善皮肤病治疗的新方法，在化妆品领域也很有前景。此外，我们发现患病皮肤中Na ⁺/K⁺-ATPase异常高蛋白表达；因此，这种蛋白质可能是牛皮癣的生物标志物。